title: [Use of cerebrospinal fluid (CSF) biomarkers for Alzheimer's type dementia: diagnosis in mild cognitive impairment].
abstract: An increasing number of people with mild cognitive impairment (MCI) visits a memory clinic to find out whether their symptoms indicate Alzheimer's disease (AD). Markers in cerebrospinal fluid are increasingly used for the diagnosis of Alzheimer's disease. In the short term, CSF biomarkers are more accurate in ruling out progression to AD-type dementia than demonstrating progression. The predictive value of the CSF biomarkers increases with longer-duration follow-up and declines with age. The added value of CSF biomarkers is not yet clear in MCI patients in whom extensive clinical, neuropsychological examination or imaging have already been performed.
authors.affiliation: MUMC, Alzheimer Centrum Limburg, Maastricht, the Netherlands. f.verhey@maastrichtuniversity.nl
authors.forename: Frans R J
authors.initials: FR
authors.lastname: Verhey
authors.forename: Pieter J
authors.initials: PJ
authors.lastname: Visser
mesh_terms: D000375:Aging; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000175:diagnosis*; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D015415:Biomarkers / Q000134:cerebrospinal fluid*; D003072:Cognition Disorders / Q000134:cerebrospinal fluid / Q000175:diagnosis; D060825:Cognitive Dysfunction / Q000503:physiopathology*; D003704:Dementia / Q000134:cerebrospinal fluid / Q000175:diagnosis; D006801:Humans; D011237:Predictive Value of Tests; D013997:Time Factors
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers